

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD.
Petitioner,

v.

REGENERON PHARMACEUTICALS, INC.
Patent Owner.

Patent No. 10,888,601

Inter Partes Review No. IPR2023-00739

PATENT OWNER'S UPDATED EXHIBIT LIST

Updated Exhibit List

Exhibit Description	Exhibit #
U.S. 10,888,601 Patent Disclaimer (July 11, 2022)	2001
U.S. 10,888,601 Patent Disclaimer (July 25, 2023)	2002
Jean-Francois Korobelnik et al., <i>Intravitreal Aflibercept for Diabetic Macular Edema</i> , 121 OPTHALMOLOGY 2247 (2014)	2003
LUCENTIS® Label (rev. Aug. 2012)	2004
Declaration of David M. Brown, M.D., <i>Mylan Pharms. Inc. v. Regeneron Pharms., Inc.</i> , IPR2021-00880, Ex.2050 (Feb. 10, 2022)	2005
Prema Abraham et al., <i>Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2</i> , 150 AM. J. OPTHALMOLOGY 315 (2010)	2006
<i>Retinal Physician Symposium Covers Broad Range of Topics</i> , Retinal Physician (Sept. 1, 2006), https://www.retinalphysician.com/issues/2006/september-2006/retinal-physician-symposium-covers-broad-range-of .	2007
DME and VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] Investigation of Clinical Impact (DA VINCI), https://classic.clinicaltrials.gov/ct2/show/study/NCT00789477	2008
Trial Transcript (unsealed portions), <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.)	2009
Press Release, Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication (Dec. 18, 2013)	2010
Provisional Application No. 61/432,245 (Jan. 13, 2011)	2011
Mylan Pharmaceuticals Inc.'s Answer, Defenses, and Counterclaims to Plaintiff's Complaint, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 47 (filed Aug. 25, 2022)	2012

Exhibit Description	Exhibit #
Complaint for Patent Infringement, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 1 (filed Aug. 2, 2022)	2013
Order on Claim Construction, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 427 (filed Apr. 19, 2023)	2014
Scheduling Order, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 87 (filed Oct. 25, 2022)	2015
Regeneron’s Stipulation Regarding Summary Judgment and Case Narrowing, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 433 (filed Apr. 27, 2023)	2016
Stipulation and Order Joining Biocon Biologics Inc. as Defendant, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 523 (filed June 5, 2023)	2017
Defendant’s Opening Post Trial Brief - Issues Where Defendants Bear the Burden of Proof, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 576 (filed July 7, 2023)	2018
Order Setting Briefing Schedule, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 514 (filed May 30, 2023)	2019
Transcript of the Status Conference held on Sept. 28, 2022, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 90 (filed Nov. 2, 2022)	2020
Irene Barbazetto et al., <i>Dosing Regimen and The Frequency of Macular Hemorrhages in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab</i> , 30 RETINA 1376 (2010)	2021
Michael Engelbert et al., <i>The “Treat and Extend” Dosing Regimen of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration</i> (June 2010) www.visioncareprofessional.com/emails/amdupdate/index42.htm	2022

Exhibit Description	Exhibit #
David S. Boyer et al., <i>A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration</i> , 116 OPTHALMOLOGY 1731 (2009)	2023
Declaration of Kira A. Davis in Support of this Motion for Admission <i>Pro Hac Vice</i> (“Davis Decl.”).	2024
Declaration of Daralyn J. Durie in Support of this Motion for Admission <i>Pro Hac Vice</i> (“Durie Decl.”)	2025
Default Protective Order	2026 [NEW]

Date: January 17, 2024

Respectfully Submitted,

By: /Adam R. Brausa/
Adam R. Brausa, Reg. No. 60,287
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105
Tel: (415) 268-6053
ABrausa@mofo.com

Counsel for Patent Owner

Certificate of Service (37 C.F.R. § 42.6(e)(4))

I hereby certify that the attached PATENT OWNER'S UPDATED EXHIBIT LIST was served on the date listed below via email (by agreement) upon the following counsel of record for Petitioner.

Raymond N. Nimrod (Reg. No. 31,987)
Matthew A. Traupman (Reg. No. 50,832)
Elliot Choi (*pro hac vice* to be applied for)
Zachariah Summers (*pro hac vice* to be applied for)
Sarah Cork (*pro hac vice* to be applied for)
Landon Andrew Smith (Reg. No. 79,248)
QUINN EMANUEL URQUHART & SULLIVAN, LLP
51 Madison Ave., 22nd Floor
New York, NY 10010
raynimrod@quinnemanuel.com
matthewtraupman@quinnemanuel.com
elliotchoi@quinnemanuel.com
zachsummers@quinnemanuel.com
landonsmith@quinnemanuel.com
qe-samsungbioepis@quinnemanuel.com

Dated: January 17, 2024

/Adam R. Brausa/
Adam R. Brausa, Reg. No. 60,287